ClinicalTrials.gg
CompletedNCT03961932Updated Mar 5, 2020

Safety and Pharmacokinetics of Linzagolix in Female Subjects With Normal and Impaired Renal Function

A Phase 1 interventional study of Linzagolix in Renal Impairment and Healthy Participants, sponsored by ObsEva SA. Completed at 2 sites in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-03-05.

Sponsored by ObsEva SA · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Jan 2020, 6 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
33
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 553 studies in Renal Insufficiency with a site in United States — 40 open to participants now, 57 under way, 3 of them phase 3. Renal Insufficiency · United States.

Enrollment
211th of 468
33 · median 32
Started
2019
with 24 others
Phase 1
232 of 553
14 open now
Registered
395th of 553
by date

Among the 553 studies in Renal Insufficiency with a site in United States, this one is the 211th largest by enrollment of the 468 interventional ones that give a count, is one of 25 that started in 2019, is one of 232 in phase 1, and was the 395th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

40 of the 553 studies in Renal Insufficiency with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 553 studies in Renal Insufficiency with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to assess the pharmacokinetics (PK) of linzagolix in subjects with varying degrees of impaired renal function compared to matched control subjects with normal renal function

Read the detailed description

This is a Phase 1, non-randomized, open label, single-dose study to evaluate the effect of varying degrees of impaired renal function (i.e., mild, moderate, severe Renal Impairment (RI), and End-Stage Renal Disease (ESRD) on hemodialysis) on the PK, safety, and tolerability of linzagolix and its major metabolite, KP017.

Up to 40 adult female participants will be enrolled.

03

Conditions studied

  • Renal Impairment
  • Healthy Participants

Keywords

  • Linzagolix
  • OBE2109
  • Renal impairment
  • Renal Insufficiency
  • Kidney Diseases
  • Clinical pharmacology study
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

Renal Impaired Subjects

  1. Adult female, ≥ 18 years of age at screening
  2. Has a ≥ 18.0 and ≤ 42.0 kg/m\^2 and weight ≥ 40 kg, at screening
  3. Aside from RI, be sufficiently healthy for study participation based upon medical history, physical examination, vital signs, (ECGs), and screening clinical laboratory profiles, as deemed by the Principal Investigator (PI) or designee

    Subjects with mild, moderate, or severe RI:

  4. Has estimated (eGFR) based on Modification of Diet in Renal Disease (MDRD) equation at screening as follows:

    • Severe RI only: ≤ 29 mL/min/1.73m\^2 not on hemodialysis
    • Moderate RI only: 30 - 59 mL/min/1.73m\^2
    • Mild RI only: 60 - 89 mL/min/1.73m\^2
  5. Has a stable renal function with no change in renal status at least 1 month prior to study drug administration and is not currently or has not been previously on hemodialysis for at least 1 year

    Subjects with ESRD:

  6. Subject is maintained on a stable hemodialysis regimen at least 3 times a week for at least 3 months prior to dosing

Healthy Subjects

  1. Health adult female will be matched to subjects with RI
  2. Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs or ECGs, as deemed by the PI or designee
  3. Baseline eGFR ≥ 90 mL/min/1.73m\^2 at screening, based on the MDRD equation. Actual , as determined by a 24-hour urine collection, may be used in place of or in conjunction with the MDRD equation at the PI's discretion

Key Exclusion Criteria:

Renal Impaired Subjects

  1. Had any major surgery within 4 weeks prior to dosing
  2. Presence of functioning renal transplant
  3. Has a surgical (e.g., hepatectomy, nephrectomy, digestive organ resection) or medical condition other than RI which might significantly alter the absorption, distribution, metabolism, or excretion of linzagolix and its metabolites, or which may jeopardize the subject's safety in case of participation in the study, in the opinion of the PI or designee

Healthy Subjects

  1. Has any clinically significant illness, as judge by the PI or designee, within 4 weeks prior to dosing
  2. Has laboratory values at screening or check-in which are deemed to be clinically significant (especially derangement within liver function test), unless agreed in advance by the PI and the Sponsor
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Normal Renal Function

    Healthy participants with Normal Renal Function (estimated Glomerular Filtration Rate (eGFR) ≥ 90 mL/min/1.73m\^2)

    Drug: Linzagolix

  • Experimental
    Mild Renal Impairment

    Presence of Mild Renal Impairment (eGFR 60-89 mL/min/1.73m\^2)

    Drug: Linzagolix

  • Experimental
    Moderate Renal Impairment

    Presence of Moderate Renal Impairment (eGFR 30-59 mL/min/1.73m\^2)

    Drug: Linzagolix

  • Experimental
    Severe Renal Impairment

    Presence of Severe Renal Impairment (eGFR ≤ 29 mL/min/1.73m\^2), not on hemodialysis

    Drug: Linzagolix

  • Experimental
    End-Stage Renal Disease

    Presence of End-Stage Renal Disease (ESRD) requiring hemodialysis

    Drug: Linzagolix

Interventions

  • A single dose of 200 mg linzagolix (2 tablets of 100 mg) will be administered orally under fasting conditions

06

What researchers measure

Primary outcomes

  1. Plasma pharmacokinetic (PK) parameter Cmax of linzagolix and of KP017

    Measurement of effect of renal impairment on PK of linzagolix and its metabolite KP017 by assessment of the maximum plasma concentration (Cmax). Cmax directly determined from the plasma concentration-time profiles

    Time frame: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose

  2. Plasma PK parameter Tmax of linzagolix and of KP017

    Measurement of effect of renal impairment on PK of linzagolix and its metabolite KP017 by assessment of the Time to reach Cmax (Tmax)

    Time frame: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose

  3. Plasma PK parameter AUC0-t of linzagolix and of KP017

    Measurement of effect of renal impairment on PK of linzagolix and its metabolite KP017 by assessment of the AUC0-t (area under the concentration time curve, from time 0 to the last observed non-zero concentration)

    Time frame: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose

  4. Plasma PK parameter T1/2 of linzagolix and of KP017

    Measurement of effect of renal impairment on PK of linzagolix and its metabolite KP017 by assessment of the T1/2 (Terminal half life)

    Time frame: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose

Secondary outcomes

  1. Treatment emergent Adverse Events

    Assessment of safety and tolerability of a single dose linzagolix in renal impaired subjects compared with healthy control subjects by assessing the number, frequency and severity of treatment emergent Adverse Events

    Time frame: Day 1 to 14 days post-dose

07

Study locations

2 sites
  • Clinical Site
    Orlando, Florida 32809, United States
  • Clinical Site
    Saint Paul, Minnesota 55114, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2019 to primary completion in Jan 2020, 8 months.

Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 8 months is close to that.

Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2019
First posted
May 23, 2019
StartActual
May 15, 2019
Primary completionActual
Jan 22, 2020
CompletionActual
Jan 31, 2020
Last update
Mar 5, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03961932
Lead sponsor
ObsEva SA
Responsible party
Sponsor
First posted
May 23, 2019
Start date
May 15, 2019
Primary completion
Jan 22, 2020
Completion
Jan 31, 2020
Last update
Mar 5, 2020

Study contacts

ObsEva SA
study director · Geneva

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linzagolix

Start the discussion